At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PRTG Portage Biotech Inc.
Not Yet Opened 11-21 16:00:00 EST
4.52
-0.05
-1.09%
盘后4.59
+0.07+1.55%
16:00 EST
High4.70Low4.19Vol51.65K
Open4.68D1 Closing4.57Amplitude11.16%
Mkt Cap4.74MTradable Cap3.34MTotal Shares1.05M
T/O231.57KT/O Rate6.99%Tradable Shares739.39K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Portage Biotech's Market Cap Drops To US$4.3m Leaving Insiders With Losses
Simply Wall St.  ·  11-17
Portage Biotech's Market Cap Drops To US$4.3m Leaving Insiders With Losses
Portage Biotech Welcomes New Financial Leadership
TIPRANKS  ·  10-05
Portage Biotech Welcomes New Financial Leadership
Portage Biotech: on Sept 30, Allan Shaw, CFO Departed From Co
THOMSON REUTERS  ·  10-05
Portage Biotech: on Sept 30, Allan Shaw, CFO Departed From Co
Portage Biotech Inc - on Sept 30, Andrea Park, as Chief Financial Officer Joined Co
THOMSON REUTERS  ·  10-05
Portage Biotech Inc - on Sept 30, Andrea Park, as Chief Financial Officer Joined Co
Protagonist Therapeutics participates in a conference call with JPMorgan
TIPRANKS  ·  09-25
Protagonist Therapeutics participates in a conference call with JPMorgan
Form 144 | Portage Biotech's Director Steven Mintz proposes to sell 7577 Shares, with a total value of approximately $121,245.19.
SEC Track  ·  09-23
Form 144 | Portage Biotech's Director Steven Mintz proposes to sell 7577 Shares, with a total value of approximately $121,245.19.
Form 144 | Portage Biotech's Director Gregory Bailey proposes to sell 70,000 shares, with a total value of approximately $1.24 Million.
SEC Track  ·  09-20
Form 144 | Portage Biotech's Director Gregory Bailey proposes to sell 70,000 shares, with a total value of approximately $1.24 Million.
Portage Biotech Regains Nasdaq Compliance
TIPRANKS  ·  09-04
Portage Biotech Regains Nasdaq Compliance
Portage Biotech : Regains Compliance With Nasdaq Listing Rule 5550(a)(2)
THOMSON REUTERS  ·  09-04
Portage Biotech : Regains Compliance With Nasdaq Listing Rule 5550(a)(2)
Portage Biotech Shares Down 2.5%
THOMSON REUTERS  ·  08-28
Portage Biotech Shares Down 2.5%
Portage Biotech Shares Fall 6.1% Premarket
THOMSON REUTERS  ·  08-28
Portage Biotech Shares Fall 6.1% Premarket
Portage Biotech Shares Down 3.1% After Reporting Q1 Share Loss, Says Still Exploring Strategic Alternatives
THOMSON REUTERS  ·  08-27
Portage Biotech Shares Down 3.1% After Reporting Q1 Share Loss, Says Still Exploring Strategic Alternatives
Portage Biotech Reports Decreased Quarterly Loss
TIPRANKS  ·  08-27
Portage Biotech Reports Decreased Quarterly Loss
Portage Biotech Shares Down 4.2% Premarket After Reporting Q1 Share Loss, Says Still Exploring Strategic Alternatives
THOMSON REUTERS  ·  08-27
Portage Biotech Shares Down 4.2% Premarket After Reporting Q1 Share Loss, Says Still Exploring Strategic Alternatives
Portage Biotech Q2 EPS $(1.58) Up From $(6.69) YoY
Benzinga  ·  08-27
Portage Biotech Q2 EPS $(1.58) Up From $(6.69) YoY
Portage Biotech Inc - Exploring Strategic Alternatives Including a Sale of Co, Merger, Restructurings, Company Wind Down
THOMSON REUTERS  ·  08-27
Portage Biotech Inc - Exploring Strategic Alternatives Including a Sale of Co, Merger, Restructurings, Company Wind Down
Portage Biotech Inc: Continue to Explore Strategic Alternatives
THOMSON REUTERS  ·  08-27
Portage Biotech Inc: Continue to Explore Strategic Alternatives
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update
THOMSON REUTERS  ·  08-27
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2024 and Business Update
Portage Biotech Inc- Qtrly Shr Loss $1.58
THOMSON REUTERS  ·  08-27
Portage Biotech Inc- Qtrly Shr Loss $1.58
Portage Biotech- Plan to Replace 1 Patient in Adport-601 Trial Who Withdrew Prior to Dose Limiting Toxicity Assessment for Unrelated Adverse Event
THOMSON REUTERS  ·  08-27
Portage Biotech- Plan to Replace 1 Patient in Adport-601 Trial Who Withdrew Prior to Dose Limiting Toxicity Assessment for Unrelated Adverse Event

Introduction

Company Name.
Portage Biotech Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.
Issue price:
--